Sulfasalazine-induced Renal and Hepatic Injury in Rats and the Protective Role of Taurine

Overview

Journal Bioimpacts

Specialty Biomedical Engineering

Date 2016 Jun 25

PMID 27340618

Citations 22

Authors

Reza Heidari

Maryam Rasti

Babak Shirazi Yeganeh

Hossein Niknahad

Arastoo Saeedi

Asma Najibi

Affiliations

Soon will be listed here.

Abstract

Introduction: Sulfasalazine is a drug commonly administrated against inflammatory-based disorders. On the other hand, kidney and liver injury are serious adverse events accompanied by sulfasalazine administration. No specific therapeutic option is available against this complication. The current investigation was designed to evaluate the potential protective effects of taurine against sulfasalazine-induced kidney and liver injury in rats.

Methods: Male Sprague-Dawley rats were administered with sulfasalazine (600 mg/kg, oral) for 14 consecutive days. Animals received different doses of taurine (250, 500 and 1000 mg/ kg, i.p.) every day. Markers of organ injury were evaluated on day 15(th), 24 h after the last dose of sulfasalazine.

Results: Sulfasalazine caused renal and hepatic injury as judged by an increase in serum level of creatinine (Cr), alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and alkaline phosphatase (ALP). The levels of reactive oxygen species (ROS) and lipid peroxidation were raised in kidney and liver of sulfasalazine-treated animals. Moreover, tissue glutathione reservoirs were depleted after sulfasalazine administration. Histopathological changes of kidney and liver also endorsed organ injury. Taurine administration (250, 500 and 1000 mg/kg/day, i.p) alleviated sulfasalazine-induced renal and hepatic damage.

Conclusion: Taurine administration could serve as a potential protective agent with therapeutic capabilities against sulfasalazine adverse effects.

Citing Articles

Safety assessment of sulfasalazine: a pharmacovigilance study based on FAERS database.

Ye W, Ding Y, Li M, Tian Z, Wang S, Liu Z Front Pharmacol. 2024; 15:1452300.

PMID: 39329122 PMC: 11424536. DOI: 10.3389/fphar.2024.1452300.

A narrative review and new insights into the protective effects of taurine against drug side effects.

Keshavarzi M, Naraki K, Razavi B, Hosseinzadeh H Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(1):203-230.

PMID: 39141023 DOI: 10.1007/s00210-024-03331-0.

Inflammatory Bowel Disease Therapies and Acute Liver Injury.

Catanzaro R, Marotta F, Yazdani A, Sciuto M Toxics. 2024; 12(6).

PMID: 38922101 PMC: 11209202. DOI: 10.3390/toxics12060421.

Gpr75 knockout mice display age-dependent cone photoreceptor cell loss.

Vasudevan S, Samuels I, Park P J Neurochem. 2023; 167(4):538-555.

PMID: 37840219 PMC: 10777681. DOI: 10.1111/jnc.15979.

Hepatic encephalopathy complications are diminished by piracetam via the interaction between mitochondrial function, oxidative stress, inflammatory response, and locomotor activity.

Niknahad H, Mobasheri A, Arjmand A, Rafiei E, Alidaee S, Razavi H Heliyon. 2023; 9(10):e20557.

PMID: 37810869 PMC: 10551565. DOI: 10.1016/j.heliyon.2023.e20557.

References

Moezi L, Heidari R, Amirghofran Z, Nekooeian A, Monabati A, Dehpour A . Enhanced anti-ulcer effect of pioglitazone on gastric ulcers in cirrhotic rats: the role of nitric oxide and IL-1β. Pharmacol Rep. 2013; 65(1):134-43. DOI: 10.1016/s1734-1140(13)70971-x. View

Jobanputra P, Amarasena R, Maggs F, Homer D, Bowman S, Rankin E . Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events. BMC Musculoskelet Disord. 2008; 9:48. PMC: 2329632. DOI: 10.1186/1471-2474-9-48. View

Boyer D, Li B, Fyda J, Friedman R . Sulfasalazine-induced hepatotoxicity in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1989; 8(4):528-32. DOI: 10.1097/00005176-198905000-00018. View

Dwarakanath A, Michael J, Allan R . Sulphasalazine induced renal failure. Gut. 1992; 33(7):1006-7. PMC: 1379424. DOI: 10.1136/gut.33.7.1006. View

Bosgelmez I, Soylemezoglu T, Guvendik G . The protective and antidotal effects of taurine on hexavalent chromium-induced oxidative stress in mice liver tissue. Biol Trace Elem Res. 2008; 125(1):46-58. DOI: 10.1007/s12011-008-8154-3. View

Linares V, Alonso V, Albina M, Belles M, Sirvent J, Domingo J . Lipid peroxidation and antioxidant status in kidney and liver of rats treated with sulfasalazine. Toxicology. 2008; 256(3):152-6. DOI: 10.1016/j.tox.2008.11.010. View

Heidari R, Babaei H, Eghbal M . Amodiaquine-induced toxicity in isolated rat hepatocytes and the cytoprotective effects of taurine and/or N-acetyl cysteine. Res Pharm Sci. 2015; 9(2):97-105. PMC: 4311296. View

Pardi D, Tremaine W, Sandborn W, McCARTHY J . Renal and urologic complications of inflammatory bowel disease. Am J Gastroenterol. 1998; 93(4):504-14. DOI: 10.1111/j.1572-0241.1998.156_b.x. View

Zulli A . Taurine in cardiovascular disease. Curr Opin Clin Nutr Metab Care. 2010; 14(1):57-60. DOI: 10.1097/MCO.0b013e328340d863. View

10.

Jagadeesan G, Sankarsami Pillai S . Hepatoprotective effects of taurine against mercury induced toxicity in rats. J Environ Biol. 2008; 28(4):753-6. View

11.

Rubin R . Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis. Am J Gastroenterol. 1994; 89(5):789-91. View

12.

Hansen S . The role of taurine in diabetes and the development of diabetic complications. Diabetes Metab Res Rev. 2001; 17(5):330-46. DOI: 10.1002/dmrr.229. View

13.

Alonso V, Linares V, Belles M, Albina M, Sirvent J, Domingo J . Sulfasalazine induced oxidative stress: a possible mechanism of male infertility. Reprod Toxicol. 2008; 27(1):35-40. DOI: 10.1016/j.reprotox.2008.10.007. View

14.

Oliveira M, Minotto J, de Oliveira M, Zanotto-Filho A, Behr G, Rocha R . Scavenging and antioxidant potential of physiological taurine concentrations against different reactive oxygen/nitrogen species. Pharmacol Rep. 2010; 62(1):185-93. DOI: 10.1016/s1734-1140(10)70256-5. View

15.

Manna P, Sinha M, Sil P . Taurine plays a beneficial role against cadmium-induced oxidative renal dysfunction. Amino Acids. 2008; 36(3):417-28. DOI: 10.1007/s00726-008-0094-x. View

16.

Plosker G, Croom K . Sulfasalazine: a review of its use in the management of rheumatoid arthritis. Drugs. 2005; 65(13):1825-49. DOI: 10.2165/00003495-200565130-00008. View

17.

Gisbert J, Gonzalez-Lama Y, Mate J . 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2007; 13(5):629-38. DOI: 10.1002/ibd.20099. View

18.

de Abajo F, Montero D, Madurga M, Garcia Rodriguez L . Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol. 2004; 58(1):71-80. PMC: 1884531. DOI: 10.1111/j.1365-2125.2004.02133.x. View

19.

Chesney R, Han X, Patters A . Taurine and the renal system. J Biomed Sci. 2010; 17 Suppl 1:S4. PMC: 2994373. DOI: 10.1186/1423-0127-17-S1-S4. View

20.

Li C, Deng Y, Sun B . Taurine protected kidney from oxidative injury through mitochondrial-linked pathway in a rat model of nephrolithiasis. Urol Res. 2009; 37(4):211-20. DOI: 10.1007/s00240-009-0197-1. View